NIH R01 · 2024
PROJECT SUMMARY/ABSTRACT Tens of thousands of otherwise deadly cancers are cured worldwide each year by hematopoietic stem cell transplantation (HCT), but unfortunately over one in ten patients will develop a viral lower respiratory tract infection, with almost half of these patients succumbing to the infection. Without an intact immune system in the first few months after transplant, these life-threatening infections offset the benefit derived from potentially life- saving transplant. Over half of these infections are caused by four viruses: RSV, HMPV, HPIV3, and HPIV1, none of which currently have any pharmacologic interventions for treatment or prevention after HCT. Although adults are…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.